This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cristofanilli, M. Articles by Hortobágyi, G. N. Search for Related Content PubMed PubMed Citation Articles by Cristofanilli, M. Articles by Hortobágyi, G. N.

Update on the Management of Inflammatory Breast Cancer

Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Correspondence: Massimo Cristofanilli, M.D., Department of Breast Medical Oncology, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 424, Houston, Texas 77030, USA. Telephone: 713-792-2817; Fax: 713-794-4385; e-mail: mcristof{at}mdanderson.org

Inflammatory breast cancer (IBC) is the most aggressive manifestation of primary breast carcinoma, with the clinical and biological characteristics of a rapidly proliferating disease. The multidisciplinary management of IBC has changed in the past 3 decades and is presently clearly outlined in sequence, with preoperative or neoadjuvant chemotherapy representing the mainstay of treatment. Anthracyclines and taxanes are the most effective cytotoxic agents in the management of primary breast cancer and should be the standard of treatment for women with IBC. Locoregional treatment includes radiotherapy with or without surgery and continues to play a major role after appropriate medical treatment. The many investigations into the particular molecular determinants of IBC development have provided several interesting new therapeutic targets. Combination regimens that include angiogenic modulators, farnesyl transferase inhibitors, and p53 modulators hold great promise in the medical management of IBC. Future therapeutic approaches should focus on these discoveries so that we can improve the overall prognosis for women with IBC.

Key Words. Inflammatory breast cancer • Targeted therapies

This article has been cited by other articles:

				M. Mego, U. De Giorgi, L. Hsu, N. Ueno, V. Valero, S. Jackson, E. Andreopoulou, S.-W. Kau, J. M. Reuben, and M. Cristofanilli Circulating tumor cells in metastatic inflammatory breast cancer Ann. Onc., June 25, 2009; (2009) mdp207v1. [Abstract] [Full Text] [PDF]

				J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al. Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose J. Clin. Oncol., February 1, 2009; 27(4): 535 - 541. [Abstract] [Full Text] [PDF]

				S. Johnston, M. Trudeau, B. Kaufman, H. Boussen, K. Blackwell, P. LoRusso, D. P. Lombardi, S. Ben Ahmed, D. L. Citrin, M. L. DeSilvio, et al. Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib Monotherapy J. Clin. Oncol., March 1, 2008; 26(7): 1066 - 1072. [Abstract] [Full Text] [PDF]

				N Cabioglu, Y Gong, R Islam, K. Broglio, N Sneige, A Sahin, A. Gonzalez-Angulo, P Morandi, C Bucana, G. Hortobagyi, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer Ann. Onc., June 1, 2007; 18(6): 1021 - 1029. [Abstract] [Full Text] [PDF]

				K. W. Hance, W. F. Anderson, S. S. Devesa, H. A. Young, and P. H. Levine Trends in Inflammatory Breast Carcinoma Incidence and Survival: The Surveillance, Epidemiology, and End Results Program at the National Cancer Institute J Natl Cancer Inst, July 6, 2005; 97(13): 966 - 975. [Abstract] [Full Text] [PDF]

				A. M. Gonzalez-Angulo, P. Morandi, and M. Cristofanilli Inflammatory Breast Cancer and High-Dose Chemotherapy: Back to the Past J. Clin. Oncol., June 1, 2005; 23(16): 3859 - 3860. [Full Text] [PDF]

				F. Bertucci, P. Finetti, J. Rougemont, E. Charafe-Jauffret, N. Cervera, C. Tarpin, C. Nguyen, L. Xerri, R. Houlgatte, J. Jacquemier, et al. Gene Expression Profiling Identifies Molecular Subtypes of Inflammatory Breast Cancer Cancer Res., March 15, 2005; 65(6): 2170 - 2178. [Abstract] [Full Text] [PDF]

				F. Bertucci, P. Finetti, J. Rougemont, E. Charafe-Jauffret, V. Nasser, B. Loriod, J. Camerlo, R. Tagett, C. Tarpin, G. Houvenaeghel, et al. Gene Expression Profiling for Molecular Characterization of Inflammatory Breast Cancer and Prediction of Response to Chemotherapy Cancer Res., December 1, 2004; 64(23): 8558 - 8565. [Abstract] [Full Text] [PDF]

				I. Bieche, F. Lerebours, S. Tozlu, M. Espie, M. Marty, and R. Lidereau Molecular Profiling of Inflammatory Breast Cancer: Identification of a Poor-Prognosis Gene Expression Signature Clin. Cancer Res., October 15, 2004; 10(20): 6789 - 6795. [Abstract] [Full Text] [PDF]

				G. Somlo, P. Frankel, W. Chow, L. Leong, K. Margolin, R. Morgan Jr, S. Shibata, P. Chu, S. Forman, D. Lim, et al. Prognostic Indicators and Survival in Patients With Stage IIIB Inflammatory Breast Carcinoma After Dose-Intense Chemotherapy J. Clin. Oncol., May 15, 2004; 22(10): 1839 - 1848. [Abstract] [Full Text] [PDF]

				M. Cristofanilli, E. S. Singletary, and G. N. Hortobagyi Inflammatory Breast Carcinoma: The Sphinx of Breast Cancer Research J. Clin. Oncol., January 15, 2004; 22(2): 381 - 383. [Full Text] [PDF]

				S. H. Giordano Update on Locally Advanced Breast Cancer Oncologist, December 1, 2003; 8(6): 521 - 530. [Abstract] [Full Text] [PDF]